Status:
WITHDRAWN
Real Life Evaluation of SGLT2 Use in Type 1 Diabetes
Lead Sponsor:
Steno Diabetes Center Copenhagen
Conditions:
Diabetic Ketoacidosis
Eligibility:
All Genders
18-90 years
Brief Summary
The primary aim of the study is to prospectively monitor the risk of diabetic ketoacidosis (DKA) during treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes after the tr...
Detailed Description
SGLT2 inhibitors have recently been approved for treatment of type 1 diabetes. SGLT2 inhibitors affect renal glucose transport and promotes glucose excretion in the urine. This have attractive effects...
Eligibility Criteria
Inclusion
- All patiens with type 1 diabetes on SGLT2 inhibitor treatment or where this treatment is planned.
Exclusion
- None
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04819178
Start Date
June 1 2021
End Date
December 1 2021
Last Update
February 28 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Steno Diabetes Center Aarhus
Aarhus, Denmark, 8200
2
Steno Diabetes Center Copenhagen
Gentofte Municipality, Denmark, 2820
3
Steno Diabetes Center Region Sjaelland
Køge, Denmark, 4600